Table 2.

Impact of paraoxon, carbachol, and nicotine

	Frequency, Hz	Peak Amplitude, pA
A. Muscarinic Receptors
Baseline (4)	1.27 ± 0.17	14.61 ± 2.62
Atropine	1.072 ± 0.23	14.74 ± 2.47
Atropine + carbachol	1.19 ± 0.33	14.51 ± 0.85
Baseline (5)	0.54 ± 0.14	13.85 ± 1.22
Atropine	0.46 ± 0.17	13.62 ± 1.62
Atropine + paraoxon	0.55 ± 0.20	14.79 ± 1.44
Baseline (4)	0.91 ± 0.14	13.70 ± 2.21
Carbachol	1.49 ± 0.43*	17.76 ± 1.69
Carbachol + atropine	1.15 ± 0.48	15.45 ± 1.08
Baseline (4)	1.18 ± 0.32	13.77 ± 1.60
Paraoxon	1.84 ± 0.60*	15.01 ± 2.03*
Paraoxon + atropine	1.21 ± 0.36	14.69 ± 1.57
B. Nicotinic receptors
Baseline (5)	1.01 ± 0.34	18.63 ± 1.93
α-bungarotoxin	1.17 ± 0.22	15.65 ± 3.08
α-bungarotoxin + nicotine	1.28 ± 0.32	15.68 ± 2.84
Baseline (4)	1.21 ± 0.16	12.049 ± 0.09
α-bungarotoxin	1.31 ± 0.18	12.04 ± 0.10
α-bungarotoxin + paraoxon	1.69 ± 0.15*	11.88 ± 0.10
Baseline (n = 5)	1.49 ± 0.38	14.59 ± 2.74
Nicotine	1.73 ± 0.42*	15.55 ± 2.76*
Nicotine + α-bungarotoxin	1.51 ± 0.45	14.75 ± 1.74
Baseline (4)	1.59 ± 0.19	11.31 ± 0.09
Paraoxon	2.36 ± 0.33**	12.08 ± 0.27*
Paraoxon + α-bungarotoxin	2.28 ± 0.30*	12.24 ± 0.42*

The impact of the cholinergic agonists paraoxon, carbachol, and nicotine coapplied with antagonists before and after application of antagonists of muscarinic or nicotinic receptors on sEPSXC frequency and amplitude.

^*P < 0.05;

^**P < 0.005 using repeated measures ANOVA test.